Katalog der Deutschen Nationalbibliothek

Go to:

Catalogue (Beta)

Knowledge Web

Person
Person

Person

Ali Afshar-Oromieh (1975-)

Arzt

Name

Ali Afshar-Oromieh

Time

1975- (Date of birth and death)

Place

Heidelberg (Wirkungsort)
Deutschland

Academic degree

Dr.

Profession

Arzt (characteristic profession)

Variant

Ali Afshar- Oromieh

Related

Klinikum Heidelberg

Further information

Diss. Medizinische Fakultät, geb. in Tehran (Iran); Oberarzt, Nuklearmedizin, Radiologische Klinik, Universitätsklinikum Heidelberg

Record type

Person

GND-Identifier

130260436

Record ID

130260436

Involved in

show all

Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer—a single-centre experience of PET-guided biopsies

Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol

Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis

Feasibility and robustness of dynamic 18F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation

Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer

Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer

Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617

Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging

Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI

Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI

Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing

68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

Hepatotoxische Nebenwirkungen adenoviraler Genvektoren erster Generation
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal